CRL
US EQUITY
Health Care
Life Sciences Tools & Services
CIK: 1100682
Charles River Laboratories (CRL) Quant Factor Diagnostic & Fair Value Model
Charles River Laboratories (Ticker: CRL) is listed in the Health Care sector (Life Sciences Tools & Services). Below is its point-in-time financial profile, valuation multiples, and cross-sectional factor diagnostics.
$345.37
+1.68%
Latest Close (2026-10-23)
Market Cap: $222.14M
P/E Ratio: -
Momentum Strength
3M / 12M
+53.98%
1M: +17.30%
12M: +84.69%
Quality (ROE)
Point-in-Time
-0.21%
Trailing Return on Equity
Technical Trend
RSI 14
69.5
SMA50: $293.94
SMA200: $218.11
Valuation Multiplier
Trailing
-
Pre-Profit / Negative TTM
📊
Valuation & Multi-Factor Diagnostic
Pre-Profit / Negative TTM
CRL has negative or near-zero trailing GAAP earnings over the trailing twelve months.
⚡
Benchmark Factor Strategy
S&P 500 Momentum Alpha Strategy
This strategy applies cross-sectional momentum and quality factor filters across large-cap US equities.
📈 Daily Candlestick & Volume Quant Chart
Interactive lightweight price action & volume breakdown over recent 90 trading days.
均线多头 (MA20/50)
Piotroski F-Score: 5/9 (Moderate Financial Health)
Official Point-in-Time Financial Filing History
Zero Lookahead Bias: Every financial metric is timestamped at the exact moment officially published to the market.
备案 CIK: 1100682 · 10-K 年报 / 10-Q 季报
| Form | Period End | Filing Timestamp (Point-in-Time) | Revenue | Net Income | Operating CF | EPS (Diluted) |
|---|---|---|---|---|---|---|
| 10-Q | 2026-06-27 | 2026-08-05 | - | -$1.48M | $220.80M | $-0.03 |
| 10-Q | 2025-12-27 | 2026-08-05 | - | - | - | - |
| 10-Q | 2025-06-28 | 2026-08-05 | - | $52.33M | $376.30M | $1.06 |
| 10-Q | 2026-03-28 | 2026-05-07 | - | -$14.84M | $41.08M | $-0.30 |
| 10-Q | 2025-03-29 | 2026-05-07 | - | $25.47M | $171.70M | $0.50 |
| 10-K | 2025-12-27 | 2026-02-18 | - | -$144.34M | $737.65M | $-2.91 |
| 10-K | 2024-12-28 | 2026-02-18 | - | $22.20M | $734.58M | $0.20 |
| 10-K | 2023-12-30 | 2026-02-18 | - | $474.62M | $683.90M | $9.22 |
💡 Methodology & Frequently Asked Questions
Key reference details regarding Charles River Laboratories (CRL) valuation multiples, momentum factors, and point-in-time filing conventions.
How should CRL's current valuation multiple be interpreted? ↓
CRL trades at a trailing P/E of -x within the Health Care sector (pre-profit / negative ttm). Valuation multiples are computed using trailing-twelve-month GAAP earnings against the latest close price.
What are CRL's key momentum and technical factor indicators? ↓
As of the latest close, CRL shows a 1-month return of +17.30%, 3-month return of +53.98%, and 12-month return of +84.69%, with a 14-day RSI of 69.5. Momentum factors reflect short- and intermediate-term price velocity across the equity cross-section.
What is Point-in-Time (PIT) financial data and why does it matter for CRL? ↓
Point-in-Time indexing aligns corporate fundamentals with their official public filing timestamps (Form 10-Q/10-K) rather than accounting period-end dates. This methodology eliminates lookahead bias in historical equity backtests.
How can CRL be incorporated into systematic factor models? ↓
CRL can be evaluated within customized multi-factor models or screened against cross-sectional filters (such as momentum quintiles and return on equity) to analyze historical turnover and risk-adjusted return.